Phase 2 trial of single agent ipilimumab (Anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma

Richard E. Royal, Catherine Levy, Keli Turner, Aarti Mathur, Marybeth Hughes, Udai S. Kammula, Richard M. Sherry, Suzanne L. Topalian, James C. Yang, Israel Lowy, Steven A. Rosenberg

Research output: Contribution to journalArticle

Abstract

New, effective therapies are needed for pancreatic ductal adenocarcinoma. Ipilimumab can mediate an immunologic tumor regression in other histologies. This phase II trial evaluated the efficacy of Ipilimumab for advanced pancreatic cancer. Subjects were adults with locally advanced or metastatic pancreas adenocarcinoma with measurable disease, good performance status, and minimal comorbidities. Ipilimumab was administered intravenously (3.0 mg/kg every 3 wk; 4 doses/course) for a maximum of 2 courses. Response rate by response evaluation criteria in solid tumors criteria and toxicity were measured. Twenty-seven subjects were enrolled (metastatic disease: 20 and locally advanced: 7) with median age of 55 years (27 to 68 y) and good performance status (26 with Eastern Cooperative Oncology Group performance status =0 to 1). Three subjects experienced ≥ grade 3 immune-mediated adverse events (colitis:1, encephalitis:1, hypohysitis:1). There were no responders by response evaluation criteria in solid tumors criteria but a subject experienced a delayed response after initial progressive disease. In this subject, new metastases after 2 doses of Ipilimumab established progressive disease. But continued administration of the agent per protocol resulted in significant delayed regression of the primary lesion and 20 hepatic metastases. This was reflected in tumor markers normalization, and clinically significant improvement of performance status. Single agent Ipilimumab at 3.0 mg/kg/dose is ineffective for the treatment of advanced pancreas cancer. However, a significant delayed response in one subject of this trial suggests that immunotherapeutic approaches to pancreas cancer deserve further exploration.

Original languageEnglish (US)
Pages (from-to)828-833
Number of pages6
JournalJournal of Immunotherapy
Volume33
Issue number8
DOIs
StatePublished - Oct 2010

Keywords

  • CTLA-4
  • gastrointestinal malignancies
  • immunotherapy
  • ipilimumab
  • natural killer cells
  • pancreatic cancer

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Pharmacology
  • Cancer Research

Fingerprint Dive into the research topics of 'Phase 2 trial of single agent ipilimumab (Anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma'. Together they form a unique fingerprint.

  • Cite this

    Royal, R. E., Levy, C., Turner, K., Mathur, A., Hughes, M., Kammula, U. S., Sherry, R. M., Topalian, S. L., Yang, J. C., Lowy, I., & Rosenberg, S. A. (2010). Phase 2 trial of single agent ipilimumab (Anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma. Journal of Immunotherapy, 33(8), 828-833. https://doi.org/10.1097/CJI.0b013e3181eec14c